← Back to Analyst Consensus 
OPK Buy
OPKO HEALTH, INC.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 1 reiterations from 2 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 16, 2026 | Piper Sandler | reiterate | Overweight → Overweight | — | 54% |
| Oct 16, 2026 | Barrington Research | upgrade | Market Perform → Outperform | — | 56% |
| Apr 29, 2026 | Barrington Research | downgrade | Outperform → Market Perform | — | 56% |
| Mar 2, 2026 | Barrington Research | maintain | Outperform → Outperform | — | 56% |
| Nov 20, 2025 | JP Morgan | initiate | — → Neutral | $0 | 54% |
| Oct 31, 2025 | Jefferies | downgrade | Buy → Hold | $1.6 | 52% |
| Oct 30, 2025 | Barrington Research | maintain | Outperform → Outperform | $2.25 | 56% |
| May 1, 2025 | Barrington Research | maintain | Outperform → Outperform | $2.25 | 56% |
| Apr 25, 2025 | JP Morgan | initiate | — → Neutral | $0 | 54% |
| Apr 7, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Mar 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Mar 12, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Mar 12, 2025 | Barrington Research | maintain | Outperform → Outperform | $2.25 | 56% |
| Mar 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Feb 28, 2025 | Barrington Research | maintain | Outperform → Outperform | $2.25 | 56% |
| Jan 8, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $3 | 44% |
| Nov 8, 2024 | Barrington Research | maintain | Outperform → Outperform | $2.25 | 56% |
| Sep 26, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Sep 20, 2024 | Barrington Research | maintain | Outperform → Outperform | $2.25 | 56% |
| Sep 17, 2024 | Piper Sandler | reiterate | Overweight → Overweight | $3 | 54% |
| Sep 17, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Aug 8, 2024 | Barrington Research | maintain | Outperform → Outperform | $2.25 | 56% |
| Jul 18, 2024 | Piper Sandler | maintain | Overweight → Overweight | $3 | 54% |
| May 8, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Apr 3, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Apr 1, 2024 | Barrington Research | maintain | Outperform → Outperform | $1.5 | 56% |
| Apr 1, 2024 | Piper Sandler | reiterate | Overweight → Overweight | $5 | 54% |
| Feb 28, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Feb 28, 2024 | Barrington Research | maintain | Outperform → Outperform | $1.5 | 56% |
| Aug 7, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Jun 29, 2023 | Barrington Research | upgrade | Market Perform → Outperform | $2 | 56% |
| May 5, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $3 | 44% |
| Mar 9, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $3 | 44% |
| Feb 24, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $3 | 44% |
| Dec 15, 2022 | HC Wainwright & Co. | initiate | — → Buy | $3 | 44% |
| Aug 5, 2022 | Piper Sandler | maintain | — → Overweight | $4 | 54% |
| May 10, 2022 | Piper Sandler | maintain | — → Overweight | $5 | 54% |
| Jan 24, 2022 | Barrington Research | downgrade | Outperform → Market Perform | $0 | 56% |
| Jun 21, 2021 | Ladenburg Thalmann | initiate | — → Buy | $7 | 45% |
| Nov 25, 2019 | Piper Sandler | initiate | — → Overweight | $2.5 | 54% |
| Mar 2, 2018 | JP Morgan | downgrade | Neutral → Underweight | $0 | 54% |
| Sep 14, 2017 | JP Morgan | downgrade | Overweight → Neutral | $7 | 54% |
| Aug 18, 2017 | Cantor Fitzgerald | initiate | — → Overweight | $20 | 50% |
| Mar 14, 2017 | Guggenheim | initiate | — → Buy | $25 | 52% |
| Dec 30, 2016 | Standpoint Research | reiterate | Buy → Buy | $0 | — |
| Jun 16, 2016 | Deutsche Bank | maintain | — → Hold | $10 | 57% |
| Jun 3, 2016 | Standpoint Research | initiate | — → Buy | $0 | — |
| Mar 31, 2016 | Barrington Research | maintain | — → Outperform | $16 | 56% |
| Oct 16, 2015 | JP Morgan | initiate | — → Overweight | $14 | 54% |
| Aug 12, 2015 | Laidlaw & Co. | initiate | — → Buy | $22 | 20% |
Price Target Trend
Apr 25, 2026 Latest: $4.15 Oct 24, 2026
EPS Estimates
+1q $-0.06
Lo: $-0.07 Hi: $-0.04
3 analysts ▲1
0y $-0.21
Lo: $-0.22 Hi: $-0.20
2 analysts ▲1
+1y $-0.34
Lo: $-0.48 Hi: $-0.26
3 analysts ▲1
0q $-0.06
Lo: $-0.08 Hi: $-0.05
3 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days